FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Biotech Weathers a Market Storm in February
March 15th, 2007
While the 416-point plunge in the Dow industrials on the penultimate day of the month took the wind out of biotech's sails, which up until then was performing ahead of the general markets, it did not completely ruin what was a strong performance by biotechs. The Burrill Biotech Select Index held its own in February, up slightly at 0.24% in contrast to the Dow, which finished down 3.2% and the NASDAQ down 2.2%. It could have been much worse but, fortunately, Wall Street rebounded somewhat on the closing day as investors took comfort from comments by Federal Reserve Chairman Ben Bernanke but still remained uneasy about the economy. He allayed some of the fears about an economic slowdown in...
Source: FDA Law Weekly (2007-03-15)
|
